ArticleOncotarget2013
Cross-species genomic and epigenomic landscape of retinoblastoma.
Article in Oncotarget, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 39 citations in OpenAlex.
- Multifocal cerebral and orbital neoplastic lesions in a 2-year-old child: a case report and literature review emphasizing diagnostic uncertainty and ethical decision-making.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Review
- Bringing p53 Back: A Prion-Powered Attack on Retinoblastoma.International journal of biological sciences · 2025Article
- Translational screening platform to evaluate chemotherapy in combination with focal therapy for retinoblastoma.Cancer science · 2023Article
- Retinoblastoma from human stem cell-derived retinal organoids.Nature communications · 2021Article
- The Xiangya Ocular Tumor Bank: A Disease-Specific Biobank for Advancing Translational Research Into Ocular Tumors.Frontiers in medicine · 2021Article
- Retinoblastoma: Etiology, Modeling, and Treatment.Cancers · 2020Review
- High levels of global genome methylation in patients with retinoblastoma.Oncology letters · 2020Article
- Nucleome Dynamics during Retinal Development.Neuron · 2019Article
- A three-dimensional organoid model recapitulates tumorigenic aspects and drug responses of advanced human retinoblastoma.Scientific reports · 2018Article
- Chromatin remodeling protein HELLS is upregulated by inactivation of the RB-E2F pathway and is nonessential for osteosarcoma tumorigenesis.Oncotarget · 2018Article
- Epigenetic regulators Rbbp4 and Hdac1 are overexpressed in a zebrafish model of RB1 embryonal brain tumor, and are required for neural progenitor survival and proliferation.Disease models & mechanisms · 2018Article
- Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235.Oncotarget · 2017Article
- CRISPR/Cas9 mediated knockout of rb1 and rbl1 leads to rapid and penetrant retinoblastoma development in Xenopus tropicalis.Scientific reports · 2016Article
- Lessons from Retinoblastoma: Implications for Cancer, Development, Evolution, and Regenerative Medicine.Trends in molecular medicine · 2016Review
- The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities.Developmental biology · 2016Article
- Orchestrating epigenetic roles targeting ocular tumors.OncoTargets and therapy · 2016Review
- Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer.Cancer research · 2015Review
- Demethylation of microRNA-142 induced by demethylation agents plays a suppressive role in osteosarcoma cells.Oncology letters · 2015Article
- Transgenic Models in Retinoblastoma Research.Ocular oncology and pathology · 2015Review
- Single and Multiple Gene Manipulations in Mouse Models of Human Cancer.Cancer growth and metastasis · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
Genetically engineered mouse models (GEMMs) of human cancer are important for advancing our understanding of tumor initiation and progression as well as for testing novel therapeutics. Retinoblastoma is a childhood cancer of the developing retina that initiates with biallelic inactivation of the RB1 gene. GEMMs faithfully recapitulate the histopathology, molecular, cellular, morphometric, neuroanatomical and neurochemical features of human retinoblastoma. In this study, we analyzed the genomic and epigenomic landscape of murine retinoblastoma and compared them to human retinoblastomas to gain insight into shared mechanisms of tumor progression across species. Similar to human retinoblastoma, mouse tumors have low rates of single nucleotide variations. However, mouse retinoblastomas have higher rates of aneuploidy and regional and focal copy number changes that vary depending on the genetic lesions that initiate tumorigenesis in the developing murine retina. Furthermore, the epigenetic landscape in mouse retinoblastoma was significantly different from human tumors and some pathways that are candidates for molecular targeted therapy for human retinoblastoma such as SYK or MCL1 are not deregulated in GEMMs. Taken together, these data suggest there are important differences between mouse and human retinoblastomas with respect to the mechanism of tumor progression and those differences can have significant implications for translational research to test the efficacy of novel therapies for this devastating childhood cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.